2-(3-hydroxyphenyl)-9-(2-isopropylphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide | 1022156-05-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(3-hydroxyphenyl)-9-(2-isopropylphenyl)-8-oxo-8,9-dihydro-7H-purine-6-carboxamide
• 英文别名: 2-(3-hydroxyphenyl)-8-oxo-9-(2-propan-2-ylphenyl)-7H-purine-6-carboxamide
• CAS: 1022156-05-3
• 化学式: C₂₁H₁₉N₅O₃
• 分子量: 389.414
• InChiKey: TTZKZDUNODWIBB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  121
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS
  申请人：Signal Pharmaceuticals LLC

  公开号：EP2078018B1

  公开（公告）日：2012-03-14
• PROCESSES FOR GENERATING ENGINEERED CELLS AND COMPOSITIONS THEREOF
  申请人：Juno Therapeutics, Inc.

  公开号：US20210163893A1

  公开（公告）日：2021-06-03

  The present disclosure provides processes for genetically engineering T cells, such as primary CD4+ T cells and/or CD8+ T cells, for use in cell therapy that does not involve expanding the cells. In particular aspects, the provided processes successfully generate compositions of engineered T cells, such as containing populations of engineered T cells, that express a chimeric antigen receptor (CAR) within a shortened amount of time as compared to alternative engineering processes, such as processes that involve expanding the cells. In certain aspects, the provided processes successfully generate a composition of engineered T cells suitable for use in cell therapy within 4 days from when the process to stimulate or activate the cells is initiated. In some aspects, the resulting engineered cell compositions are composed of cell population that are less differentiated, less exhausted, and more potent than engineered T cell compositions generated by other means, such as by processes that involve expanding the cells. Also provided are compositions of T cells generated by the provided methods and their uses for treating subjects.
• PROCESS FOR PRODUCING A T CELL COMPOSITION
  申请人：Juno Therapeutics, Inc.

  公开号：US20210254000A1

  公开（公告）日：2021-08-19

  Provided herein are methods for producing engineered T cells that express a recombinant receptor, such as for use in cell therapy. In some aspects, the provided methods include one or more steps for incubating the cells under stimulating conditions, introducing a recombinant polypeptide to the cells through transduction or transfection, and/or cultivating the cells under conditions that promote proliferation and/or expansion, in which one or more steps is carried out in the presence of an agent that inhibits mammalian target of rapamycin (mTOR) activity. In some aspects, cultivation is performed in the presence of an agent that inhibits mammalian target of rapamycin (mTOR) activity. In some aspects, the provided methods produce genetically engineered T cells with improved persistence and/or anti-tumor activity in vivo.
• METHODS FOR SELECTION AND STIMULATION OF CELLS AND APPARATUS FOR SAME
  申请人：Juno Therapeutics GmbH

  公开号：US20220002669A1

  公开（公告）日：2022-01-06

  Provided herein are methods for selecting and stimulating a plurality of cells in a sample of cells using column chromatography, and collecting the cells without using additional steps or reagents to facilitate detachment of the cells from the column. In some aspects, the methods provided herein reduce the time needed to generate a population of selected and stimulated cells useful for genetic engineering, and ultimately, cell therapy, compared to existing methods. Also provided are articles of manufacture and apparatus thereof.